CD8A and neoplasm: For example, using CD8+ T-cell radiolabeled with 89Zr, Alsaid and colleagues found that the number of CD8 T-cells increased in the TDLN’s, already 4 days after the start of ICOS/anti-PD-1 treatment, and in the tumor 11 days after (23).